The seized vaccines, valued at around Rs 2 lakh, were identified as counterfeit after the original manufacturer, Human Biological Institute in Telangana, confirmed that the concerned batch had not been manufactured or supplied by the company.

The case has also led investigators to Kanpur in Uttar Pradesh, where officials have conducted further raids following information provided during the Delhi investigation.

Fake Abhayrab vaccine seized

The operation was carried out after the Delhi Drugs Control Department received information about the suspected sale of counterfeit medicines.

Officials searched a sales premises and a warehouse in Bhagirath Palace and recovered 481 units of “Rabies Vaccine, Human I.P. (Purified Vero Cell Rabies Vaccine) – Abhayrab.”

The department contacted the original manufacturer to verify the batch. The company confirmed that it had not released the recovered vaccine and that the products were counterfeit.

Officials retained 120 vials as samples and seized the remaining 361 units, along with seven purchase invoices. The action was taken under relevant provisions of the Drugs and Cosmetics Act, 1940.

The samples have been sent to the Central Research Institute (CRI) in Kasauli for testing and analysis.

Also Read | El Niño could be linked to 4.5 lakh additional heat-related deaths by February 2027, report says

Also Read | Banks announce nationwide strike for three days from September 28: What customers need to know ?

Counterfeit drug trail leads to Kanpur

During questioning, the Delhi-based firm allegedly told investigators that it had purchased the counterfeit vaccine from an agency in Kanpur.

The information was shared with the Uttar Pradesh Drugs Control Department, following which the UP team conducted raids at two locations in Kanpur.

According to the information provided by the Delhi department, the agency in Kanpur admitted to supplying the suspected counterfeit vaccine to Delhi.

Investigators are now working to trace the wider supply network, including the source of the fake vaccines, their distribution route and the people allegedly operating the racket.

Delhi Health Minister orders strict action

Delhi Health Minister Dr Pankaj Kumar Singh has taken serious note of the seizure and said there would be no compromise on the quality and safety of medicines.

He stressed that rabies is a serious and potentially fatal disease and said strict action would be taken against those involved in the sale or distribution of fake and adulterated medicines.

Authorities said the investigation will continue to identify other people linked to the alleged network and determine how widely the counterfeit vaccine was distributed.

Officials have also warned that those found responsible could face legal action under the provisions of the Drugs and Cosmetics Act, 1940.

Patiala and Mohali have emerged as the next major hotspots, with 49 cases each. Jalandhar has recorded 21 cases, while Amritsar has reported 15 patients.

The district-wise figures provided are as follows:

• Ludhiana: More than 90 cases; 1 death
• Patiala: 49 cases
• Mohali: 49 cases
• Jalandhar: 21 cases; 1 death
• Amritsar: 15 cases
• Moga: 14 cases
• Hoshiarpur: 13 cases
• Rupnagar (Ropar): 12 cases
• Bathinda: 11 cases
• Malerkotla: 9 cases
• Sangrur: 9 cases
• Gurdaspur: 8 cases
• Ferozepur: 6 cases
• Faridkot: 5 cases
• Fatehgarh Sahib: 5 cases
• Kapurthala: 4 cases
• Pathankot: 4 cases
• Tarn Taran: 4 cases
• Barnala: 2 cases
• Fazilka: 2 cases
• Muktsar: 2 cases
• Mansa: 1 case

What is swine flu?

Swine flu is a commonly used term for illness caused by certain strains of influenza A virus, particularly the H1N1 strain. Although the virus was first associated with outbreaks in pigs, H1N1 now circulates among humans as a seasonal influenza virus.

For most people, the infection causes a respiratory illness that can be managed with appropriate care. However, some patients can develop serious complications, particularly those who are at higher risk.

Also Read | Delhi LG Taranjit Singh Sandhu launches Rs 1.46-lakh limited-edition Golden Temple book, urges publishers to cut price

How does swine flu spread?

H1N1 spreads in much the same way as other seasonal influenza viruses. An infected person can release virus-containing respiratory droplets when coughing, sneezing or talking. The infection can also spread when a person touches contaminated surfaces and subsequently touches their mouth, nose or eyes.

Close contact with an infected individual can therefore increase the risk of transmission, particularly in crowded or poorly ventilated settings.

Common symptoms of swine flu

Symptoms can develop after exposure to the virus and may include:

• Fever or feeling feverish
• Cough
• Sore throat
• Runny or blocked nose
• Headache
• Body aches and muscle pain
• Chills
• Fatigue or weakness
• Sometimes vomiting or diarrhoea, particularly in children
• Symptoms can vary from person to person, and not everyone with influenza will experience every symptom.

Who may face a higher risk of complications?

While many people recover without major problems, influenza can become more serious in certain groups. These include older adults, young children, pregnant women and people with certain underlying medical conditions or weakened immune systems.

Complications can include pneumonia and worsening of existing medical conditions.

Is swine flu fatal?

Yes, H1N1 infection can be fatal, but deaths are uncommon compared with the large number of people who recover. The risk depends on factors such as the person's age, overall health, severity of infection and whether complications develop.

Precautions to reduce the risk

• Wash hands regularly with soap and water or use an alcohol-based hand sanitiser.
• Cover the mouth and nose while coughing or sneezing.
• Avoid close contact with people who are sick.
• Avoid touching the eyes, nose and mouth with unwashed hands.
• Stay home and limit contact with others when experiencing influenza-like symptoms.
• Improve ventilation in indoor spaces where possible.
• People at higher risk of complications should seek medical advice promptly if flu symptoms develop.
• Anyone experiencing difficulty breathing, chest pain, persistent dizziness, confusion, severe weakness or symptoms that improve and then suddenly worsen should seek urgent medical attention.

The order covers more than just their sale. The manufacturing, storage and distribution of gutka and pan masala containing tobacco or nicotine have also been prohibited.

The order was issued by Food Safety Commissioner Mandip Singh Brar and was published in the Chandigarh administration's gazette on September 18. The restriction will remain in force for one year from the date of the order.

Also Read | Pathankot: Missile-like shell found in UBDC canal, security tightened

Also Read | Sikh bus driver assaulted, beard pulled and vehicle stolen before it crashes in UK; assailant arrested| Watch

The administration said the prohibition applies to tobacco and nicotine-containing products marketed under different names and brands.

The action has been taken under the Food Safety and Standards Act, 2006. The order also refers to Regulation 2.3.4 of the Food Safety and Standards (Prohibition and Restriction on Sales) Regulations, 2011.

The regulation prohibits the use of tobacco and nicotine as ingredients in food products.

Anyone found manufacturing, storing, selling or distributing products covered by the order could face action under the relevant food safety laws.

Administration cites health concerns

The Chandigarh Administration said the move was taken in the public interest, citing the health risks associated with products containing tobacco and nicotine.

The fresh order comes at a time when the UT administration is also stepping up its focus on tackling the illegal drug trade.

Police given September 30 deadline on drug trade

Recently, UT Administrator Gulab Chand Kataria directed the police and administration to take steps to eliminate the illicit drug trade and set September 30 as the deadline.

He warned that station house officers and field-level personnel could face action if illegal drug sales continued after the deadline.

The ED said Mangla was arrested by its Hyderabad office on September 17. He was subsequently produced before a special Prevention of Money Laundering Act (PMLA) court in Visakhapatnam, which sent him to judicial custody.

According to the agency, its investigation found that ghee supplied to the Tirumala Tirupati Devasthanams (TTD) as Agmark Special Grade Cow Ghee was allegedly made using several vegetable oils and chemical substances.

The agency alleged that the products used in the manufacturing process included refined palm oil, palm kernel oil and palmolein. It also named chemicals such as MG-90, monoglycerides, Myvacet Soft 400 and acetic acid ester.

The ED said the alleged fraudulent supply of ghee to TTD between 2019 and 2024 was worth around Rs 230 crore. Of this, the agency alleged that Mangla was involved in manufacturing adulterated ghee valued at approximately Rs 96 crore.

Also Read | Asian Games 2026: Five Indian debutants who could make a big mark in Japan

ED alleges role in supply network

The agency has described Mangla as one of the alleged co-conspirators in the case. It claimed that he helped arrange adulterants and manufactured the allegedly adulterated ghee at his factory.

The ED further alleged that the product was supplied to TTD through several entities, including Sri Vyshnavi Dairy Specialities, Malganga Milk & Agro Products and A.R. Dairy Foods.

Investigators also accused Mangla of maintaining false records related to the purchase and sale of ghee and refined palm oil.

According to the ED, these records were allegedly created to hide the actual use of adulterants and make the supplies appear to be genuine cow ghee.

Another promoter already arrested

Mangla is the second promoter to be arrested by the ED in connection with the case. Earlier, the agency arrested Vipin Jain, promoter and director of Bhole Baba Organic Dairy Milk, over similar allegations.

The ED's investigation is continuing. The agency has alleged that adulterated products were supplied as cow ghee for use in preparing the famous Tirupati Laddu prasadam.

According to a legal notice, the products under scrutiny are NAN Excella Pro Stage 1, Lactogen Pro 1 and a follow-up formula manufactured by Nestle India.

Also Read: Surendra Kohli, acquitted in 2006 Nithari killings case, dies by suicide in Haridwar

The Food Safety and Standards Authority of India (FSSAI) examined the products and their promotional material listed on e-commerce platforms. The regulator raised concerns about certain promotional claims and also found an issue with the nutritional composition of one follow-up formula sample.

However, the action does not mean that the Nestle products have been banned. The notice relates to adjudication proceedings over alleged regulatory violations. Starting these proceedings also does not mean that all batches of the products are unsafe.

The final decision will depend on the findings of the competent authority during the adjudication process.

What was flagged in NAN Excella Pro Stage 1?

According to the notice, promotional material for NAN Excella Pro Stage 1 carried claims related to “5 HMOs” and “Whey Protein.”

FSSAI sought an explanation from Nestle India about these claims. The regulator later stated that the product was in violation of Regulation 4(2) of the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020.

What Was fagged in Lactogen Pro 1?

FSSAI also examined promotional material for Lactogen Pro 1.

The material reportedly described whey protein as being easy to digest. The regulator sought clarification from Nestle India and later stated that the product also violated Regulation 4(2) of the 2020 regulations.

The regulation places restrictions on promotional practices for foods meant for infants.

Why are promotional claims restricted ?

Infant nutrition products are subject to strict regulations because they are meant for babies during an important stage of their development.

Indian rules restrict advertising and promotional activities for infant foods to ensure that marketing does not influence decisions about infant feeding.

The FSSAI notice also refers to the Infant Milk Substitutes, Feeding Bottles and Infant Foods (Regulation of Production, Supply and Distribution) Act, 1992.

The law places restrictions on the advertising and promotion of infant milk substitutes and certain infant foods.

How many cases are filed against Nestle India

The notice says that three separate adjudication cases have been filed against Nestle India Limited in connection with the three products.

Two cases relate to alleged violations involving promotional claims, while the third concerns a laboratory finding related to the biotin content of a follow-up formula.

These cases are part of the adjudication process. The alleged violations will be examined by the relevant authority before any final action or penalty is decided.

Researchers from Queen’s University Belfast analysed findings from 29 studies that examined the relationship between exposure to air pollution and suicidal behaviour. Their findings were published in the Journal of Epidemiology and Community Health.

The researchers said the results suggest that environmental factors that can potentially be reduced should also be considered when developing strategies to prevent suicide. They stressed that suicide prevention should not be viewed only through the lens of mental health, as individual, biological, social and environmental factors can interact in complex ways.

PM2.5 and PM10 linked to short-term risk

The statistical analysis found a significant association between short-term exposure to PM2.5 and PM10 and an increased risk of suicide and suicidal behaviour. Longer-term exposure to PM2.5 and NO2 was also associated with higher risks of suicide, suicide attempts and suicidal thoughts.

Researchers noted that some other pollutants, including sulphur dioxide and ozone, may also be linked to suicidal behaviour, although the evidence for these pollutants was less consistent.

PM2.5 refers to very fine particles that can penetrate deep into the respiratory system, while PM10 consists of larger airborne particles. Nitrogen dioxide is commonly produced by combustion processes, including vehicle traffic and other sources.

How pollution could affect the brain

The researchers pointed to previous evidence suggesting that exposure to certain environmental pollutants can affect the nervous system. They also noted that contaminated water containing substances such as arsenic, lead, lithium or nitrate has been associated with adverse neurological effects.

Such exposure may contribute to processes, including inflammation and damage to the nervous system, which can affect brain function, mood and the body's ability to respond to stress.

However, the researchers stressed that the relationship between pollution and suicidal behaviour is complex. Factors such as mental health, personal circumstances and biological differences can also influence suicide risk.

More research needed

The researchers said considerable work has already examined links between air pollution and conditions such as depression and anxiety, but comparatively less research has focused specifically on suicide and suicidal thoughts.

Professor Ben Mullins of the School of Population Health at Curtin University in Australia, who was not involved in the study, said the review is among the early broad analyses examining the relationship between air pollution and suicide.

Mullins noted that several pollutants, particularly some metals, are already known to affect the nervous system and have been associated with mental health conditions such as depression and anxiety. He said the findings therefore add to existing evidence suggesting a possible connection between environmental pollution and mental health outcomes.

ALSO READ | Canada study visa rules change: Students must show more funds from September 1

The 10-year-old boy, a resident of Durgapur, West Bengal, was diagnosed with a second relapse of acute lymphoblastic leukemia (ALL)in April this year. The family travelled to Punjab to continue his treatment at HBCH&RC, a unit of Tata Memorial Centre under the Department of Atomic Energy (Government of India). Following intensive chemotherapy, he achieved remission. However, considering the high risk of reoccurrence, an allogeneic stem cell transplant was recommended as the best curative treatment.

An allogeneic bone marrow transplant, also called a stem cell transplant, is a treatment in which a patient’s diseased blood-forming system (bone marrow) is replaced with healthy blood-forming stem cells obtained from another person. 

“The patient’s elder sister was identified as the most suitable donor after detailed donor evaluation. Her stem cells were collected and infused into her brother through a vein. The transplanted cells successfully engrafted and, following close monitoring and supportive care, the child has now recovered and was discharged from the hospital, in good health, on Tuesday. We will continue to closely monitor him during the post-transplant period”, said Pediatric Hematologist-Oncologist and BMT physician, Dr Jasmeet Sidhu. 

“Transplantations requires meticulous planning, precise donor selection, infection prevention and intensive supportive care. The hospital’s medical oncology department, with a dedicated Paediatric oncology unit, is equipped with modern treatment facilities like monoclonal antibodies, Chimeric Antigen Receptor T-cell (CAR-T) therapy, immunotherapies and targeted therapies for adult and paediatric patients. It is pertinent to mention that the treatment here is highly subsidised,” head of the department of medical oncology, Dr Seema Gulia, said.

Director, HBCH &RC Punjab, Dr Ashish Gulia, said, “For us, this is not only a medical milestone but a deeply human one. This story of young brother and sister, shows the hope that advanced cancer care can offer to families facing some of the most difficult moments of their lives. We ensured that the patient’s family is supported medically, emotionally, as well as financially. The hospital’s Medical Social Work team facilitated over Rs 14 lakh in financial assistance through government schemes and CSR support, besides arranging accommodation for the family in dharamshala during treatment.”

“Since the inception of BMT programme in 2024, the hospital has performed 15 stem cell transplants and three CAR-T cell therapy infusions, so that patients with difficult-to-treat blood cancers can access potentially curative treatment. We are committed in providing world-class cancer treatment at affordable cost, in entire North India”, Dr Gulia added.

A Bench of Justices JB Pardiwala and K Vinod Chandran on Thursday asked the food regulator why such warnings could not have been made mandatory from the outset. The court also sought clarity on what the FSSAI meant by a “reasonable period” for implementing the proposed labelling system.

The Bench questioned the need for a two-stage rollout suggested by the FSSAI and sought an explanation for the proposed timeline.

The issue came up during the hearing of a public interest litigation (PIL) seeking mandatory front-of-pack warning labels on packaged food products.

Also Read | Can children under 18 use social media without parental consent? SC seeks Centres response 

Supreme Court focuses on children's health

During the hearing, the Bench referred to the UNICEF Child Nutrition Report 2025 while raising concerns about increasing rates of overweight and obesity among school-age children and adolescents.

The court also highlighted the difference between food available inside schools and what children can buy around school premises. It noted that nearly 80% of food and beverages available within schools are freshly prepared meals, while close to 80% of the food sold around schools consists of packaged snacks.

“We are only concerned about the health of people, especially growing children. We want all the concerned to consider the cause in national interest,” the Bench observed.

The Supreme Court has given the Centre 10 days to file its response.

Court asks Centre about nutritional education in schools

The court also called on the government to consider introducing nutritional education as part of school curricula.

The Centre has been asked to explain how schools could promote nutritional awareness through classroom teaching, programmes and workshops.

The court further sought details on how consumers, particularly students and families, should understand the information printed on packaged food, including nutritional details and the proposed Front-of-Pack Labelling (FoPL).

SC questions proposed red hexagon warning

The Bench also raised a concern about the proposed design of the warning label.

The FSSAI has suggested using a red-coloured hexagon on the front of packages to alert consumers about products high in specified nutrients. However, the Supreme Court observed that the shape could potentially confuse consumers because of its similarity to the existing symbol used to identify non-vegetarian food.

The matter has been listed for further hearing on September 28.

What is FSSAI's proposed front-of-pack warning label?

The FSSAI had earlier informed the Supreme Court that it was considering a prominent red warning label for packaged foods containing high levels of added saturated fat, added sugar and salt.

In its compliance affidavit, the regulator said the purpose of the proposed system was to give consumers a simple and easily understandable warning about products containing high amounts of nutrients considered a health concern.

Under the proposal, a red hexagonal warning would appear on products that are high in any two or more of the specified nutrients, added saturated fat, added sugar and salt.

The thresholds would be based on the Dietary Guidelines for Indians, 2024, issued by the ICMR-NIN.

Depending on the product, the label could carry declarations such as “High Fat”, “High Sugar”, “High Salt” and/or “Highly Sweetened Beverage”.

The objective is to allow consumers to identify products containing high levels of these nutrients without having to study the entire nutritional information panel.

The FSSAI submitted the affidavit in compliance with the Supreme Court's August 13 order in the ongoing PIL.

The petition seeks directions to the Centre, states and Union territories to introduce mandatory front-of-pack warning labels for packaged food products.

The inspections have taken place across Kolkata and other parts of the state over the past few days. The findings have raised concerns as restaurants and food outlets are expected to see a major increase in customers during the festive season.

The latest enforcement drive comes at a time when Maharashtra Food and Drug Administration Commissioner Tukaram Mundhe has also been in the news for his strict action against food establishments. His enforcement campaign has drawn attention to food safety checks in other states as well.

Also Read | Rajya Sabha MP Raghav Chadha's name missing from Punjab voter rolls, he alleges 'AAP's political vendetta'

Also Read | Air India Express flight makes emergency landing in Lucknow; 155 passengers and crew evacuated

Baduria in North 24 Parganas has once again come under the scanner. The area was at the centre of the 2018 carcass meat scandal that had shocked West Bengal. During an inspection, officials reportedly recovered around 40 kg of rotten chicken and mutton from a restaurant in Baduria.

The restaurant reportedly told officials that the meat had been kept separately and was meant to be thrown away. Authorities, however, were not satisfied with the explanation and issued a notice to the establishment.

Expired food found at Star Mall

Food safety teams also carried out inspections at Star Mall in Kolkata, a busy shopping and entertainment destination.

Officials reportedly found rotten meat and expired food packets at several food court outlets. Some establishments were allegedly operating without the required licences, while poor hygiene was also found in some kitchens.

At one restaurant, inspectors reportedly discovered chicken affected by fungus inside a refrigerator. Some food items were allegedly thrown into dustbins after the inspection team arrived.

Following the inspection, the licence of the restaurant was cancelled, according to reports.

500 kg stale chicken and prawns seized in Tangra

In another major action, a Chinese restaurant in Tangra, Kolkata's well-known Chinatown area, was temporarily ordered to shut by the Kolkata Municipal Corporation on Wednesday.

Officials reportedly seized nearly 500 kg of stale raw chicken and prawns from the restaurant's kitchen.

Tangra is known for its many affordable Chinese and Indo-Chinese restaurants and attracts large numbers of customers.

Food safety checks spread across Bengal

The inspections are not limited to Kolkata.

In Shaktigarh, famous for its Bengali sweet called Langcha, food officials reportedly found ingredients and food products that were considered unfit for consumption during checks at sweet shops.

Several irregularities involving food storage and the use of colouring agents were also reported at dhabas in East Midnapore.

In Digha, another major tourist destination, officials inspected around 20 hotels. Chemical-based colours were reportedly found being used in biryani preparation. Notices were issued to 12 restaurants.

A sweet shop in Hooghly was also reportedly found using gulaal to colour sweets. The shop owner told officials that the colours had been left over from Holi. Officials did not accept the explanation.

Food safety drive launched ahead of Durga Puja

The inspections come as the state government is conducting a food safety campaign from September 1 to September 8.

The drive was launched in the Hogg Market, popularly known as New Market, area. The government has stressed that it will follow a zero-tolerance approach towards food adulteration and violations of food safety rules.

With Durga Puja just weeks away, authorities are stepping up checks at restaurants, sweet shops, hotels and other food outlets.

The company has approached the court after receiving notices over the product’s labelling and advertising claims, including descriptions such as “100% Veg” and “Cholesterol Free – For Healthy Lifestyle.”

Court rejects jurisdiction objection

The authorities had questioned whether the Delhi High Court was the appropriate forum to hear the matter. Their argument was that AWL Agri Business is based in Gujarat and that the product is manufactured and marketed from outside Delhi.

Justice Swarana Kanta Sharma, however, held that the petition could not be rejected on the ground of territorial jurisdiction at this stage.

The court noted that the FSSAI authorities concerned are located within Delhi’s jurisdiction and that the actions directly challenged by the company were taken by FSSAI in Delhi. These actions also form the basis of the relief sought in the petition.

The court has given the authorities four weeks to file their responses. The matter has been listed for further hearing on November 5.

FSSAI issued show-cause notice

According to the petition, FSSAI issued a show-cause notice to the company on July 17, alleging violations of the Food Safety and Standards (Advertising and Claims) Regulations, 2018 and the Food Safety and Standards (Labelling and Display) Regulations, 2020.

The company was asked to explain within seven days why action should not be initiated against it under the Food Safety and Standards Act.

Also Read | NEET protest: CJP calls off September 5 Delhi march after Centres compensation assurance

On the same day, FSSAI also wrote to food safety commissioners in all states and Union Territories, directing them to ensure that products classified as “non-compliant” were not manufactured, distributed, marketed or sold in their respective jurisdictions.

Company claims product faced nationwide action

AWL Agri Business has argued that the FSSAI communication effectively placed its Fortune Soya Health Refined Soyabean Oil in the category of a non-compliant product.

According to the company, this exposed the product and its distributors, stockists, wholesalers and retailers to enforcement action across the country.

The petitioner further claimed that, during August, some of its distributors informed the company that food safety officials had visited their establishments and directed them to stop selling the product.

Following this, the company said several retailers stopped placing fresh orders and some also sought the return of stock already supplied.

The Delhi High Court will now consider the responses from the Centre and FSSAI before taking the matter forward.

The move came after the Bombay High Court criticised the regulator for acting in a “high-handed” manner and going “overboard” in the matter.

A bench comprising Acting Chief Justice Ravindra Ghuge and Justice Gautam Ankhad said the FDA had not followed the proper procedure before cancelling the licence. The court also raised concerns over the violation of the principles of natural justice.

Following the court’s observations, the FDA informed the bench that it would withdraw the cancellation order with immediate effect.

The regulator will now issue a fresh show-cause notice to Cipla, consider the company’s response and then pass a fresh, reasoned order.

Why was Cipla's licence cancelled?

The FDA had cancelled the drug sale licences of Cipla Pharma & Life Sciences’ C&F facility at Wadki in Pune from August 27.

The action was linked to alleged irregularities involving the packaging, storage and recall of Reactin Plus Tablets. Cipla challenged the cancellation in the Bombay High Court.

During the hearing, senior advocate Aabad Ponda, appearing for Cipla, told the court that the FDA had asked the company to appear for a hearing on August 26. However, August 26 was a public holiday in Maharashtra.

Ponda said Cipla did not have a representative available on the holiday and requested more time. Despite the request, the FDA went ahead and cancelled the licence on the same day.

The FDA’s lawyer, Additional Government Pleader P P Kakade, argued that the company did not have a legal right to a hearing.

Court questions FDA's procedure

The bench questioned why the FDA had called the company for a hearing on a public holiday and then proceeded with the cancellation after Cipla asked for an adjournment.

The judges also questioned whether the regulator’s action was fair and transparent.

The court observed that the FDA had “wronged” the company and needed to resolve the issue. It also said the department appeared to have followed an improper procedure while taking the action.

Following the court’s remarks, the FDA agreed to withdraw the cancellation order and restart the process by issuing a fresh notice to Cipla.

What did FDA find during inspection?

The FDA’s action followed inspections at Cipla’s facility. During an inspection in June, officials reportedly found promotional wording on the packaging of Reactin Plus Tablets, a Schedule H prescription medicine. The packaging mentioned that the medicine was an “analgesic and antipyretic”.

According to the FDA, such wording amounted to promotion of a prescription drug. The regulator said this could encourage people to take the medicine without medical advice and increase the risk of self-medication.

The FDA also pointed to differences between the physical stock and computer records at the facility.

Officials reported gaps in purchase and sales records as well as alleged non-compliance with directions issued for recalling the medicine.

Cipla says no product safety issue was raised

Cipla had said on Friday that it was challenging the FDA’s decision. The company also clarified that the licence cancellation order did not raise concerns about the safety, quality or effectiveness of its products.

Cipla further said the FDA’s order did not involve or indicate any issue concerning patient safety.

Also Read | FSSAI bans sale of Everest, Laljee Godhoo hing after tests find products substandard

The food regulator has asked both companies to explain the violations and submit action plans showing how they plan to meet the prescribed standards. They have also been advised to voluntarily recall the substandard hing products already available in the market.

The ban will continue until the companies comply with the required regulations.

FSSAI finds issues with other Everest products

FSSAI also found violations in three other Everest products, egg curry masala, chicken masala and garam masala. However, the regulator has not imposed a ban on the sale of these three products.

What did FSSAI find in Hing samples?

According to FSSAI, the inspection followed a consumer complaint about major hing brands. Samples were collected from the manufacturing facilities of the companies in Mumbai, along with samples from Everest's plant in Umbergaon, Gujarat.

Laboratory tests showed that the compounded hing samples did not meet the required standards.

Under the existing rules, compounded hing must contain at least 5 per cent alcohol-soluble extract. However, the samples tested by FSSAI contained only 0 to 3 per cent.

The regulator said this indicated that the products contained significantly less raw hing than the prescribed requirement.

The tests also found serious concerns in six varieties of raw hing collected from the Laljee Godhoo facility. These samples contained between 15 per cent and 32 per cent starch, while the permitted limit is only 1 per cent.

FSSAI proposes warning labels on packaged foods

The action against the hing manufacturers comes at a time when FSSAI has proposed stronger warning labels for packaged food products.

FSSAI has told the Supreme Court that it has proposed a bright red, hexagonal warning label on the front of packaged foods that contain high amounts of sugar, salt or saturated fat.

The proposal came after the Supreme Court questioned FSSAI and the government over delays in bringing front-of-pack warning labels.

The proposed labels are aimed at making it easier for consumers to identify packaged foods that contain excessive amounts of sugar, salt or saturated fat.

The move has also renewed the discussion around how clearly food companies should inform consumers about the nutritional risks linked to their products.

Also Read | BJP chief Nitin Nabin reprimands 3 Delhi MPs over visit to Sajjan Kumars home

Also Read | Big blow for India: Neeraj Chopra out of Asian Games 2026; season comes to early end

The statement came after Delhi Chief Minister Rekha Gupta held an emergency meeting to review the rising number of H1N1 cases in the city. Delhi has recorded around 3,000 influenza cases this year, including 2,308 confirmed H1N1 infections.

Isolation wards set up in hospitals

Speaking to reporters after a review meeting with senior officials from the Health Department, MCD, NDMC and Delhi Cantonment Board, Pankaj Singh said hospitals across Delhi have been prepared to handle patients requiring care.

Dedicated isolation wards for H1N1 patients have been arranged at hospitals, he said. The minister warned that strict action would be taken if any hospital refused admission or denied a bed to a patient who required hospital care.

“There is no shortage of doctors, staff or medicines,” he said, adding that the government was closely monitoring the situation.

What are the symptoms of H1N1?

H1N1, commonly known as swine flu, can cause symptoms similar to seasonal influenza. Common symptoms include:

Fever

Cough

Sore throat

Headache

Runny nose

Body aches

Tiredness or weakness

Some people may also experience watery eyes, chills and general weakness. In many cases, symptoms remain mild and improve with rest and appropriate medical care.

However, cough, tiredness and body aches can sometimes continue for several days or even weeks after the initial infection.

How does H1N1 spread?

H1N1 is a respiratory infection and can spread when an infected person coughs or sneezes. Close contact with an infected person can also increase the chances of transmission.

Health experts generally recommend regular handwashing, covering the mouth and nose while coughing or sneezing, and wearing a mask in crowded or high-risk settings when necessary.

People who are diagnosed with H1N1 should follow their doctor's advice and take appropriate precautions to avoid spreading the infection to others.

Who is at higher risk?

While many people recover without serious complications, certain groups need to be more cautious.

Older adults, people with weakened immunity and those with underlying health conditions may have a greater risk of developing severe illness.

Such individuals should seek medical advice promptly if they develop flu-like symptoms, particularly if the symptoms become severe or worsen.

Is H1N1 treatable?

Yes, H1N1 can be treated. Most cases are mild and improve with supportive care such as adequate rest, fluids and medicines recommended by a doctor.

Doctors may prescribe antiviral medicines in certain cases, especially when treatment is started early or when a patient is considered to be at higher risk of complications.

Hospitalisation may be required if a patient's condition becomes serious or if they develop complications.

Delhi health authorities have said hospitals and other civic agencies are keeping a close watch on the situation and will strengthen arrangements if required as the number of influenza cases continues to rise.

According to Delhi health department data, the capital has reported 2,392 Influenza-A cases this year, of which 1,777 were H1N1 infections. On Thursday alone, 114 H1N1 cases were recorded.

The government has urged residents to remain alert and follow basic precautions to reduce the spread of the infection.

Common symptoms of H1N1

The symptoms of H1N1 are often similar to those of seasonal influenza. The Ministry of Health has listed several common signs, including:

• Fever
• Cough
• Sore throat
• Headache
• Runny nose
• Body aches
• Fatigue

Doctors say some patients may also experience cold, watery eyes and general weakness. Experts say H1N1 infections have been particularly noticeable in Delhi-NCR this year. They attributed the increase, among other factors, to prevailing weather conditions, including high temperatures and humidity.

Doctors are of the view that most patients experience relatively mild symptoms such as fever, sore throat and cough. However, body aches and cough may continue for several weeks in some cases.

Swine flu (H1N1) can show up through symptoms such as fever, cough, sore throat, headache, runny nose, body aches and fatigue.

Recognise the signs early and don’t ignore persistent symptoms. If you experience these symptoms, seek medical advice at your nearest healthcare centre.… pic.twitter.com/9ephVereZ5

— Ministry of Health (@MoHFW_INDIA) August 22, 2026

How does H1N1 spread?

H1N1 is a respiratory infection and can spread from an infected person to others. Experts have recommended maintaining good hand hygiene and using a mask when appropriate, particularly in crowded or high-risk settings.

People who test positive should follow medical advice and remain isolated as recommended to reduce the risk of passing the infection to others.

Timely testing can also help in identifying infections and starting appropriate treatment, particularly among people who are more vulnerable to complications.

Who needs to be more careful?

People with weakened immunity, older adults and those living with underlying health conditions may face a higher risk of developing complications.

Experts have advised people in these groups to consult a doctor promptly if they develop flu-like symptoms rather than delaying medical care.

Is H1N1 treatable?

Yes. Doctors say most H1N1 infections are mild and improve with appropriate supportive care. In some cases, doctors may prescribe antiviral medication, particularly when treatment is started early or when a patient is at greater risk of complications.

While many patients recover without hospitalisation, elderly people and those in high-risk groups may require closer monitoring or hospital care if their condition worsens.

Delhi health authorities have said arrangements are being monitored and hospitals are being strengthened as required to manage the seasonal increase in infections.

Also Read | Delhi-NCR H1N1 cases surge six-fold: Swine flu spreads as doctors warn of rising respiratory infections

Doctors are treating a growing number of patients complaining of flu-like symptoms. In some cases, patients have also experienced breathing problems and falling oxygen levels, prompting closer medical monitoring.

The rise has also affected healthcare workers, with several people, including doctors and the head of a government hospital in Delhi, reportedly testing positive for H1N1.

Delhi sees 1,349 H1N1 cases

The scale of the increase is reflected in Delhi's case numbers. The capital has recorded 1,349 H1N1 cases so far this year, compared with 229 cases during the corresponding period last year.

That amounts to nearly a six-fold jump and comes during the monsoon season, when doctors often see an increase in respiratory illnesses.

However, a rise in reported cases does not mean every person with fever or cough has H1N1. Other viral and respiratory infections can cause similar symptoms, making medical evaluation important when symptoms are persistent or severe.

What are symptoms of H1N1?

H1N1 can begin suddenly and may cause symptoms similar to seasonal influenza. Common signs include:

• Sudden fever
• Dry cough
• Sore throat
• Headache
• Body aches
• Chills
• Fatigue

Most people recover without serious complications. However, some patients can develop more severe respiratory symptoms, including difficulty breathing and low oxygen levels.

When should you see a doctor?

People should not ignore symptoms that are getting worse. Medical attention is particularly important if a patient develops breathlessness, chest pain, persistent high fever, confusion, bluish lips or worsening respiratory symptoms.

A sudden drop in oxygen levels is also a reason to seek prompt medical evaluation rather than relying solely on home treatment.

Also Read | Moderna, Merck’s personalised cancer vaccine shows breakthrough results in high-risk melanoma trial

Influenza can affect anyone, but certain groups are more likely to develop complications.

These include older adults, young children and pregnant women. People living with conditions such as diabetes, chronic heart or lung disease, or weakened immunity may also face a greater risk of severe illness.

Doctors generally advise people in these groups to seek medical advice earlier if they develop flu-like symptoms.

How to protect yourself from H1N1

With respiratory infections circulating, basic precautions can help reduce the risk of transmission.

Health experts recommend maintaining good hand hygiene, covering the mouth and nose while coughing or sneezing and avoiding close contact with others when feeling unwell.

People experiencing flu-like symptoms should also consider staying home and limiting contact with vulnerable family members until they recover.

Influenza vaccination can provide additional protection, particularly for people who are at higher risk of complications. Anyone considering vaccination should speak with a healthcare professional about whether it is appropriate for them.

The vaccine was tested alongside Merck’s cancer immunotherapy Keytruda (pembrolizumab) in patients with high-risk melanoma. According to the companies, the combination met the main goal of the Phase 3 trial by reducing the risk of cancer recurrence.

The treatment also met a key secondary goal by lowering the risk of the cancer spreading to other parts of the body, a condition known as distant metastasis.

Full details of the trial are expected to be presented at a forthcoming medical conference.

What is a personalised mRNA cancer vaccine?

Unlike vaccines used to prevent infections, personalised cancer vaccines are designed for individual patients. After a tumour is removed through surgery, doctors can examine its genetic makeup and identify mutations that are specific to the cancer. The information can then be used to create a vaccine designed to help the immune system recognise and attack cancer cells carrying those mutations.

Moderna’s approach uses mRNA technology to deliver these instructions to the immune system. The aim is to create a stronger immune response against cancer cells that may remain in the body after surgery.

Keytruda combination shows encouraging results

The Phase 3 study included 1,137 patients with high-risk stage IIB to IV melanoma whose tumours had been surgically removed.

Participants received either Keytruda together with the personalised mRNA vaccine or Keytruda alone for about one year.

The companies said patients receiving the combination had a lower risk of melanoma returning compared with those treated with Keytruda alone. The treatment also reduced the risk of distant metastasis.

No new safety concerns were identified during the trial, according to Moderna and Merck.

The findings are important because Keytruda is already widely used to treat melanoma. If adding a personalised vaccine can further improve patient outcomes, it could open the door to a new way of combining immunotherapy with mRNA technology.

First positive late-stage results for personalised mRNA vaccine

Moderna and Merck described the results as the first positive Phase 3 findings for an individualised mRNA cancer vaccine. The companies believe the results could be an important step towards making personalised cancer vaccines part of future cancer treatment.

Moderna president Stephen Hoge said discussions with regulators are already underway. The treatment has also received breakthrough therapy designation, which could help speed up the regulatory process.

However, the vaccine is not yet approved for routine use. More detailed trial data will be needed to understand its full benefits, risks and long-term impact.

Importantly, the latest announcement does not yet provide final overall survival results, meaning it is still unclear whether the treatment will help patients live longer.

Earlier study had also shown positive results

The latest Phase 3 findings follow encouraging results from an earlier study of the same treatment.

In January, Moderna and Merck reported five-year follow-up data showing that the combination reduced the risk of recurrence or death by 49% compared with Keytruda alone.

The new results add further support to the idea that personalised mRNA vaccines could help prevent cancer from returning following surgery.

Researchers are also investigating similar approaches for other cancers, including lung, breast and pancreatic cancers.

What could it mean for Melanoma patients?

Melanoma is an aggressive form of skin cancer, particularly when it spreads beyond the original tumour.

For people with high-risk melanoma who have already undergone surgery, preventing the disease from returning is an important part of treatment.

A personalised vaccine could provide another layer of treatment by training the immune system to identify cancer cells based on mutations found in the patient's own tumour.

Still, patients and doctors will need to wait for the complete clinical data and regulatory decisions before knowing how the treatment could fit into standard melanoma care.

A potential new direction for cancer treatment

The results could have significance beyond melanoma. Personalised mRNA vaccines are being studied as a potential form of precision cancer treatment, with researchers looking at ways to tailor therapy to the genetic features of each patient's tumour.

If future studies continue to show that these vaccines are safe and effective, they could become an important part of treatment for several types of solid tumours.

For Moderna, the development also represents an effort to expand its mRNA technology into areas beyond infectious diseases. For Merck, combining a personalised vaccine with Keytruda could potentially create another important use for the company's established immunotherapy.

Questions remain over manufacturing, cost, large-scale production and the long-term survival benefits of the treatment. Even so, the positive late-stage results are being viewed as an important development in the search for more personalised cancer therapies.

Also Read | Telangana horror: Class 10 students stab principal to death for money, attacked 27 times; two detained

Civil Surgeon Dr Jay Prakash Singh visited the hospital and reviewed the condition of the children. He said all the students were out of danger.

According to school officials, the mid-day meal served to the students consisted of soybean rice and was supplied by an NGO according to the prescribed menu. Some students had already eaten when others complained that the food did not have enough salt.

Local residents alleged that containers of salt and detergent powder had been kept close to each other in the school kitchen. The cook reportedly mistook the detergent powder for salt and added it to the food. Soon after eating the meal, several students complained of dizziness and started vomiting.

The students were initially given first aid at the school. However, as some of them continued to feel unwell, they were taken to Sadar Hospital for further treatment.

Bihar Rural Development Minister Shravan Kumar visited the hospital and met the affected students. He also spoke with doctors about their condition.

Kumar said a detailed investigation would be carried out to determine how the alleged mistake happened during the preparation and serving of the mid-day meal.

The incident has raised questions about food handling and safety measures in school kitchens. Further details are expected after the inquiry.

Also Read | Jaggu Bhagwanpuria gang operative Major Singh added to FBI’s most wanted list

Also Read | RCMP warns Two Canadian Sikh Separatists of life threat over Khalistan-related activities

Q1: What are you seeing in terms of arthritis burden in India today?

Dr. Pandher: The shift is significant. A decade ago, the typical knee replacement patient was in their late sixties. Today, I’m routinely seeing patients in their late forties and early fifties. Sedentary lifestyles, obesity, dietary changes, all of it is accelerating joint degeneration across age groups. The burden is real, it’s growing, and it’s arriving earlier than it used to.

Q2: Many patients still delay seeking treatment despite the pain. Why does this happen?

Dr. Pandher: Fear of surgery is the biggest reason, followed by concerns about  recovery time and cost. There’s also a deep-seated tendency in India to push through pain — to treat endurance as the only option. By the time most patients reach me, they’ve been managing for years. The joint is more damaged, the surrounding muscles have weakened, and what could have been a straightforward procedure becomes more complex. The delay always has a cost.

Q3: You use an AI-assisted Precision Arthroplasty System in your surgeries. What does that actually mean for the patient on the table?

Dr. Pandher: The AI-assisted Precision Arthroplasty System brings real-time, intraoperative data into the surgical process. We attach small trackers to specific bony landmarks, and the system continuously provides highly accurate information about limb alignment, joint balance, and implant positioning as I operate. I am performing the surgery and making every decision throughout the procedure. The AI-assisted Precision Arthroplasty System does not replace the surgeon, it enhances surgical precision by providing an accurate, dynamic picture of what’s happening inside the joint at every stage of the operation. Think of it as having an exceptionally precise instrument panel.

The surgeon is still flying the aircraft, but with far more advanced instruments to guide every decision.

Q4: Who is a good candidate for knee replacement surgery?

Dr. Pandher: Any patient with advanced knee arthritis whose quality of life is significantly affected and for whom conservative management, medication, and physiotherapy have stopped delivering relief. Age is less of a barrier than people assume. What matters is the degree of joint damage and the patient’s functional goals. Younger patients want to stay active longer. Older patients want their independence back. Both are valid, and both are achievable.

Q5: What does recovery look like after a hip or knee replacement, and how do you help patients recover faster?

Dr Pandher: Recovery begins far earlier than most expect. With modern techniques, effective pain management and our AI-assisted Precision Arthroplasty System, most patients are standing and walking within hours of surgery. For select patients, we also offer day-care joint replacement; home the same day. We’re expanding this responsibly based on patient profile and support systems.

But surgery is only half the journey. Rehabilitation is equally critical. We’re based in one of India’s largest NRI belts, and many patients travel from overseas — or from Patna, Gwalior, Uttarakhand, and the Andaman Islands for their procedures at our centre. For many of them, frequent physiotherapy visits aren’t always practical. That’s why we developed a structured, video-based rehabilitation programme patients follow at home, at their own pace. Compliance and outcomes have both improved significantly. I tell every patient: stay committed to your rehabilitation and the results can be remarkable. I’ve seen patients walking unaided and climbing stairs within days. Precise surgery, a structured rehabilitation programme and an actively engaged patient changes everything.

Q6: What would you say to a patient who has been putting off this decision?

Dr. Pandher: That arthritis does not wait. Every month of delay means more cartilage loss, more muscle weakening, and a longer road to recovery after surgery. The procedure patients are afraid of today is far more precise and controlled than what they have heard about or imagined. Knee replacement surgery is clinically established, outcomes are reliable, and recovery is faster than ever. One consultation is all it takes to understand where you stand. Don’t let fear make a medical decision for you.

The decision is expected to trigger discussions across the country as authorities tighten action against food adulteration and misleading food practices.

Also Read | Air India turbulence video: Air hostess's 'Fasten Your Seat Belts' warning goes viral after Phuket-Delhi flight scare | Watch

Why has fake paneer been banned?

The Maharashtra Food and Drug Administration (FDA) has officially prohibited the manufacture, sale and distribution of analogue paneer for one year. The gazette notification was issued on July 30, 2026, by State FDA Commissioner Tukaram Mundhe.

The action comes after laboratory testing found serious quality concerns. According to the FDA, more than 35% of paneer samples collected across the state recently failed quality standards because they contained vegetable fat instead of milk fat.

Officials said such products pose a public health concern and often mislead consumers who believe they are purchasing genuine dairy paneer.

Also Read | Dubai's Jebel Ali area rocked by 7 explosion in 20 minutes, thick smoke triggers panic; cause still unknown 

Hotels, restaurants and cloud kitchens under strict watch

Under the new order, hotels, restaurants, caterers and cloud kitchens have been barred from using, preparing, serving or even storing analogue paneer.

Authorities found that several food businesses were allegedly replacing real milk paneer with cheaper artificial alternatives without informing customers or mentioning it on menus. The government believes such practices amount to consumer deception and violate food safety norms.

Genuine paneer must meet FSSAI standards

The order also directs manufacturers of genuine paneer to strictly comply with Food Safety and Standards Authority of India (FSSAI) packaging and labelling regulations.

Paneer products must now be clearly labelled according to their exact milk fat content so that consumers know what they are buying.

Industry body welcomes the decision

Reacting to the government's notification, Abhay Pandey, president of the All India Food & Drug License Holder Foundation, said the issue of analogue cheese and paneer had been under discussion for a long time.

He said the ban has now been formally implemented after Maharashtra Food Safety Commissioner Tukaram Mundhe took strong action on the matter.

According to Pandey, the commissioner acted decisively by issuing the Government Resolution (GR) to stop the use of analogue dairy products in the state.

What happens if businesses violate the ban?

The Maharashtra FDA has warned that any food business operator found violating the order could face immediate enforcement action. This includes seizure of the stock, destruction of prohibited products and heavy penalties and legal action under the Food Safety Act.

Officials have indicated that inspections will be intensified to ensure compliance with the new rules.

Why this matters beyond Maharashtra

Although the ban currently applies only to Maharashtra, the issue has national significance because paneer is one of India's most widely consumed dairy products. The move has once again highlighted concerns over food adulteration, transparency in restaurants and the need for consumers to know exactly what they are eating.

Health officials in Michigan confirmed the deaths on Monday, marking the first fatalities recorded in the country from the parasitic illness. Authorities said both individuals had underlying medical conditions, which may have increased the severity of the infection and complications caused by dehydration.

The outbreak has also raised concerns among consumers about food safety, with many asking whether simply washing vegetables is enough to eliminate the Cyclospora parasite.

Also Read | Diljit Dosanjh’s Japan vlog wins hearts: Singer struggles to find dustbins, jokes about wedding ring

Also Read | FSSAI bans Old Monk, Royal Challenge, Bagpiper over artificial flavouring in Whisky, Rum

Cyclospora is a microscopic parasite that causes cyclosporiasis, an intestinal infection that mainly affects the digestive system. People infected with the parasite commonly experience prolonged diarrhea, stomach cramps, nausea, fatigue, loss of appetite and weight loss.

In most healthy individuals, the illness is treatable and rarely becomes life-threatening. However, it can pose serious risks for older adults, people with weakened immune systems and those with existing health conditions, especially if severe dehydration develops.

FDA links outbreak to iceberg lettuce

According to the US Food and Drug Administration (FDA), the ongoing investigation has linked the outbreak across nine states to iceberg lettuce supplied by Taylor Farms from central Mexico.

Investigators are continuing to examine whether other contaminated food items may also have contributed to the spread of the infection.

Officials noted that the contaminated lettuce had already been recalled after being identified as a possible source of infection. The affected produce was reportedly used in food served at Taco Bell, operated by Yum Brands.

Record number of Cyclospora cases reported

The United States has recorded a significant rise in cyclosporiasis cases this year, making it one of the largest outbreaks reported in recent years. Public health experts believe contaminated fresh produce, particularly salad ingredients, has been one of the major drivers behind the surge in infections.

Restaurant industry feels the impact

The outbreak has affected consumer confidence in fresh salads and ready-to-eat vegetables.

Although the FDA continues to investigate additional sources of contamination, reports of new infections have continued to emerge. The situation has also impacted restaurant chains that rely heavily on fresh produce.

Industry reports indicate that salad sales have declined, while customer visits to major restaurant brands such as Sweetgreen and Chipotle have also dropped as consumers become more cautious about ordering leafy greens.

Is washing vegetables enough?

Experts say rinsing vegetables under clean running water can help remove dirt and some surface contaminants, but washing alone may not completely eliminate the Cyclospora parasite. Since the parasite can adhere to fresh produce, health authorities stress the importance of safe farming, hygienic food handling and proper supply-chain monitoring to reduce the risk of contamination.

Consumers are advised to stay informed about food recalls and seek medical attention if they develop persistent diarrhea or other symptoms after consuming potentially contaminated food.